CSIMarket
 


In Vitro & In Vivo Diagnostic Substances Industry Profitability

Profitability Information & Trends 
  
Category:   Period:  

In Vitro & In Vivo Diagnostic Substances Industry Profitability Ratios 1 Q 2024 4 Q 2023 3 Q 2023 2 Q 2023 1 Q 2023
  2024 2023 2023 2023 2023
Gross Margin 58.05 % 60.56 % 57.03 % 56.24 % 53.03 %
Gross Margin Annual (TTM) 57.73 % 59.68 % 55.79 % 55.79 % 55.96 %
Gross Margin Ranking # 31 # 36 # 39 # 42 # 41
EBITDA Margin - 23.45 % 17.07 % 13.05 % 14.23 %
EBITDA Margin Annual (TTM) 3.44 % 22.34 % 11.96 % 11.44 % 10.7 %
EBITDA Margin Ranking # 12 # 16 # 43 # 63 # 55
Operating Margin - 16.98 % 6.95 % 4.3 % 6.34 %
Operating Margin Annual (TTM) - 16.53 % 3.75 % 3.78 % 4.14 %
Operating Margin Ranking # 11 # 27 # 70 # 91 # 75
Pre-Tax Margin - 16.46 % 6.53 % 2.01 % 3.78 %
Pre-Tax Margin Annual (TTM) - 16.64 % 1.42 % 1.09 % 1.51 %
Pre-Tax Margin Ranking # 4 # 13 # 63 # 86 # 80
Net Margin - 11.27 % 3.18 % - 1.75 %
Net Margin Annual (TTM) - 11.44 % - - -
Net Margin Ranking # 5 # 19 # 75 # 97 # 86


Comment on the 1 Q 2024 Gross Margin within the In Vitro & In Vivo Diagnostic Substances Industry

In Vitro & In Vivo Diagnostic Substances Industry Gross Profits grew by 8.01 % in 1 Q 2024 sequentially, while Revenue increased by 5.12 %, this led to improvement in In Vitro & In Vivo Diagnostic Substances Industry's Gross Margin to 63.32 %, Gross Margin remained below In Vitro & In Vivo Diagnostic Substances Industry average.

On the trailing twelve months basis gross margin in 1 Q 2024 fell to 57.73 %.

Within Healthcare sector 3 other industries have achieved higher gross margin. Gross margin total ranking has impoved so far to 31, from total ranking in previous quarter at 36.

Note, Numbers include only companies who have reported earnings results. Numbers change as more businesses report financial results. See the full List.

Gross Margin Statistics
High Average Low
141.22 % 72.44 % 50.88 %
4. quarter 2020   3. quarter 2022

Gross Margin Industry Ranking
Within: No.
Healthcare Sector # 4
Overall # 31


Other Gross Margins
Compare Industry's gross margin to Lila's or S&P Gross profits within In Vitro & In Vivo Diagnostic Substances Industry
Highest Ranking Gross Margins Lowest Ranking Gross Margins
Profitability for Lila's Suppliers Definiton of Gross Margin

In Vitro & In Vivo Diagnostic Substances Industry EBITDA Margin Statistics

 
EBITDA Margin Statistics
High Average Low
103.7 % -691.34 % -7174.09 %
4. quarter 2020   4. quarter 2021

EBITDA Margin Industry Ranking
Within: No.
Healthcare Sector # 1
Overall # 12

EBITDA Margin Comment on the 1 Q 2024 within the In Vitro & In Vivo Diagnostic Substances Industry

In Vitro & In Vivo Diagnostic Substances Industry operating loss decreased compare to previous quarter.

On the trailing twelve months basis Ebitda Margin in 1 Q 2024 fell to 3.44 %.

Within Healthcare sector, In Vitro & In Vivo Diagnostic Substances Industry achieved highest ebitda margin. Ebitda margin total ranking has impoved so far to 12, from total ranking in previous quarter at 16.

Other EBITDA Margins
Compare Industry's EBITDA margin to Lila's or S&P Gross profits within In Vitro & In Vivo Diagnostic Substances Industry
Highest Ranking EBITDA Margins Lowest Ranking EBITDA Margins
Profitability for Industry's Suppliers Industry Net Cash Flow Margin


In Vitro & In Vivo Diagnostic Substances Industry Operating Margin Statistics

 

Operating Margin Comment on the 1 Q 2024 within the In Vitro & In Vivo Diagnostic Substances Industry

In Vitro & In Vivo Diagnostic Substances Industry Operating Loss decreased compare to previous quarter.



Within Healthcare sector, In Vitro & In Vivo Diagnostic Substances Industry achieved highest operating margin. Operating margin total ranking has impoved so far to 11, from total ranking in previous quarter at 27.



Operating Margin Statistics
High Average Low
30.41 % -710.06 % -7228.19 %
1. quarter 2024   4. quarter 2021

Operating Margin Industry Ranking
Within: No.
Healthcare Sector # 1
Overall # 11

In Vitro & In Vivo Diagnostic Substances Industry Pre-Tax Margin Statistics

 


Pre-Tax Margin Statistics
High Average Low
87.19 % -705.38 % -7253.84 %
4. quarter 2020   4. quarter 2021

Comment on the 1 Q 2024 Pre-Tax Margin in the In Vitro & In Vivo Diagnostic Substances Industry

In Vitro & In Vivo Diagnostic Substances Industry Pre-Tax Loss decreased compare to previous quarter.



Within Healthcare sector, In Vitro & In Vivo Diagnostic Substances Industry achieved highest Pre-Tax Margin. Pre-Tax Margin total ranking has impoved so far to 4, from total ranking in previous quarter at 13.
Pre-Tax Margin Industry Ranking
Within: No.
Healthcare Sector # 1
Overall # 4

Pre-Tax Margins
Compare Industry's pre-tax margin to Lila's or S&P Net profits within In Vitro & In Vivo Diagnostic Substances Industry
Highest Ranking Net Margins Lowest Ranking Net Margins
Profitability for Lila's Competitors Industry Tax Rate


In Vitro & In Vivo Diagnostic Substances Industry Net Margin Statistics

 





Net Margin Comment on the 1 Q 2024 in the In Vitro & In Vivo Diagnostic Substances Industry

In Vitro & In Vivo Diagnostic Substances Industry Net Loss decreased compare to previous quarter.



Within Healthcare sector, In Vitro & In Vivo Diagnostic Substances Industry achieved highest Net margin. Net margin total ranking has impoved so far to 5, from total ranking in previous quarter at 19.

Net Margin Statistics
High Average Low
61.99 % -711.22 % -7253.84 %
4. quarter 2020   4. quarter 2021
Net Margin Industry Ranking
Within: No.
Healthcare Sector # 1
Overall # 5

Other Net Margins
Compare Industry's net margin to Lila's or S&P Net profits within In Vitro & In Vivo Diagnostic Substances Industry
Highest Ranking Net Margins Lowest Ranking Net Margins
Profitability for Lila's Suppliers Definiton of Net Margin





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com